Neurotransmitters & Signal Modulation: Chemical Communication in the Nervous System
Neurotransmitters are the chemical messengers that allow neurons to communicate with one another, with skeletal muscle, and with glands. While electrical impulses allow signals to travel rapidly along neurons, it is neurotransmitters that carry those signals across synapses to influence the activity of target cells. Every thought, movement, emotion, memory, and autonomic response depends on precisely regulated neurotransmitter release and receptor activation. Because these chemicals shape nearly all nervous system activity, disruption of neurotransmitter function underlies many neurological, psychiatric, and neuromuscular disorders.
What You Need to Know
Neurons communicate through chemical synapses, where electrical signals are converted into chemical messages that cross the tiny gap between cells. When an action potential reaches the end of a neuron, calcium enters the presynaptic terminal and triggers the release of neurotransmitter into the synaptic cleft. These chemicals carry the signal from one neuron to the next, allowing information to flow through neural circuits that control sensation, movement, thought, and emotion.
An action potential triggers calcium entry into the presynaptic terminal
Neurotransmitters are released from vesicles into the synaptic cleft
They bind to specific receptors on the postsynaptic membrane
Receptors may be ionotropic (directly opening ion channels) or metabotropic (activating intracellular signalling pathways)
This produces either an excitatory or inhibitory effect on the next neuron
Once neurotransmitters bind to their receptors, they change the electrical state of the postsynaptic neuron. Excitatory signals make the neuron more likely to fire an action potential, while inhibitory signals make it less likely to fire. The brain does not rely on single synapses but instead integrates thousands of excitatory and inhibitory inputs at once, with the overall balance determining whether the neuron will send a signal onward.
To keep signalling precise and prevent continuous stimulation, neurotransmitters are quickly removed from the synaptic cleft. This occurs through reuptake into the presynaptic neuron, enzymatic breakdown, or diffusion away from the synapse. These mechanisms allow the nervous system to reset after each signal, ensuring rapid, controlled, and repeatable communication between neurons.
Beyond the Basics
Neurotransmitters belong to several major functional classes, each with characteristic actions and clinical relevance. Rather than acting in isolation, these chemical messengers work together in networks that regulate movement, sensation, cognition, mood, and autonomic function. Imbalance in any of these systems can disrupt normal brain activity and produce characteristic neurological or psychiatric disorders.
Neurotransmitters
Acetylcholine (ACh) is the primary neurotransmitter of the somatic motor system and the autonomic nervous system. At the neuromuscular junction, acetylcholine binds to receptors on skeletal muscle fibres, triggering depolarisation and muscle contraction. Within the autonomic nervous system, it is released by all preganglionic neurons and by postganglionic parasympathetic neurons, allowing it to mediate functions such as heart rate slowing, glandular secretion, and gastrointestinal activity. In the central nervous system, acetylcholine plays a major role in attention, learning, memory, and arousal by modulating cortical and hippocampal circuits. Degeneration of acetylcholine-producing neurons is a key feature of Alzheimer’s disease, contributing to memory loss and cognitive decline.
Glutamate is the principal excitatory neurotransmitter of the central nervous system. It is responsible for most fast excitatory synaptic transmission and is essential for learning, memory formation, and synaptic plasticity. Glutamate acts on several receptor types, including NMDA and AMPA receptors, which regulate calcium and sodium flow into neurons and are critical for long-term potentiation, the cellular basis of learning. When glutamate activity becomes excessive, it causes excitotoxicity, a process in which prolonged calcium influx damages or kills neurons. This mechanism contributes to neuronal injury in stroke, traumatic brain injury, epilepsy, and many neurodegenerative diseases.
Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter of the brain. It counterbalances the excitatory effects of glutamate and prevents excessive neuronal firing that could destabilise neural networks. By opening chloride channels, GABA makes neurons less likely to fire, maintaining electrical stability and controlling muscle tone, anxiety, and seizure threshold. Many sedative and anti-anxiety medications, including benzodiazepines, barbiturates, and anaesthetics, work by enhancing GABA activity, which explains their calming, muscle-relaxing, and anticonvulsant effects.
Dopamine plays a central role in movement regulation, motivation, reward, attention, and emotional behaviour. Dopaminergic pathways connect the basal ganglia, limbic system, and prefrontal cortex, allowing dopamine to influence both motor control and goal-directed behaviour. Loss of dopamine-producing neurons in the substantia nigra disrupts basal ganglia function and produces the rigidity, tremor, and bradykinesia of Parkinson’s disease. In contrast, excessive dopaminergic activity in certain brain regions is linked to psychosis and schizophrenia. Dopamine also underlies reinforcement and addiction by signalling reward and reinforcing behaviours that lead to pleasurable outcomes.
Noradrenaline (norepinephrine) is a major neurotransmitter of both the sympathetic nervous system and the brain’s alertness networks. In the periphery, it mediates many of the effects of sympathetic activation, including increased heart rate, vasoconstriction, and heightened arousal. In the central nervous system, noradrenaline is released by neurons in the locus coeruleus and enhances vigilance, attention, and responsiveness to stimuli. It also modulates mood and emotional tone, which is why dysregulation is associated with anxiety, depression, and stress-related disorders.
Serotonin (5-HT) influences mood, sleep, appetite, pain perception, emotional regulation, and gastrointestinal motility. It is produced primarily in the raphe nuclei of the brainstem and distributed widely throughout the brain, where it shapes emotional stability, impulse control, and sleep-wake cycles. In the gut, serotonin also regulates intestinal movement and secretion. Altered serotonin signalling plays a central role in depression, anxiety disorders, and many sleep disturbances, which is why selective serotonin reuptake inhibitors (SSRIs) are widely used in psychiatric treatment.
Neuropeptides, such as endorphins, enkephalins, substance P, and neuropeptide Y, act mainly as modulators rather than fast neurotransmitters. They are released alongside classical neurotransmitters and modify how strongly neurons respond over longer time periods. Endorphins and enkephalins suppress pain transmission and produce feelings of well-being, explaining their role in stress relief and placebo effects. Substance P is involved in pain and inflammation, while neuropeptide Y influences appetite, stress resilience, and autonomic function. Through these actions, neuropeptides fine-tune how neural circuits respond to physical and emotional challenges.
Signal Modulation & Integration
Neural signalling is not simply “on” or “off.” The strength, timing, and pattern of neurotransmitter release profoundly influence neural networks. Through temporal summation, repeated inputs over time can bring a neuron to threshold. Through spatial summation, inputs from multiple synapses combine to determine whether an action potential is generated. This dynamic integration allows fine-tuned control of movement, perception, emotion, and cognition.
Neurotransmitter activity is further shaped by neuromodulators, which do not directly generate EPSPs or IPSPs but instead influence how strongly a neuron responds to other signals. Dopamine and serotonin frequently act as neuromodulators, adjusting the responsiveness of entire neural circuits rather than producing immediate excitation or inhibition.
Receptor sensitivity also changes over time. Chronic exposure to high neurotransmitter levels may cause receptor down-regulation, reducing responsiveness, while low neurotransmitter levels may induce receptor up-regulation, increasing sensitivity. These adaptive changes explain many features of drug tolerance, withdrawal, and long-term effects of psychiatric medications.
Clinical Connections
Neurotransmitter dysfunction underlies a wide range of neurological and psychiatric disorders because these chemicals determine how neural circuits communicate. In Parkinson’s disease, depletion of dopamine within basal ganglia pathways disrupts the normal balance between excitation and inhibition, producing bradykinesia, rigidity, and resting tremor. In depression, altered serotonin and noradrenaline signalling affects mood regulation, sleep–wake cycles, appetite, and cognitive processing. In epilepsy, inadequate GABA-mediated inhibition allows uncontrolled neuronal firing, leading to recurrent seizures and heightened sensitivity to sensory input.
Alterations in neurotransmitter activity produce distinct and recognisable clinical effects, such as:
Dopamine deficiency: Parkinson’s disease (bradykinesia, rigidity, tremor)
Serotonin and noradrenaline dysregulation: depression, anxiety, sleep and appetite disturbance
Reduced GABA activity: epilepsy and seizure disorders
Excess glutamate: excitotoxic neuronal injury
Acetylcholine Impairment
At the neuromuscular junction, disturbances in acetylcholine signalling produce profound weakness. In myasthenia gravis, antibodies destroy or block postsynaptic acetylcholine receptors, so repeated muscle use leads to rapidly worsening fatigue and weakness that improves with rest. In botulism, acetylcholine release is blocked at the presynaptic terminal, preventing muscle fibre activation and causing progressive flaccid paralysis that can impair breathing and swallowing. These disorders demonstrate how failure of a single neurotransmitter system can compromise essential functions such as movement and respiration.
Medications and Neurotransmitters
Many commonly used medications act by modifying neurotransmitter systems. Selective serotonin reuptake inhibitors (SSRIs) increase synaptic serotonin and are widely used in depression and anxiety. Benzodiazepines enhance GABA activity, producing sedation, muscle relaxation, and anticonvulsant effects. Antipsychotic drugs reduce dopaminergic signalling to control hallucinations and delusions. Opioids act on endorphin receptors to suppress pain but also depress respiration and carry a high risk of tolerance and dependence, making close monitoring essential.
Autonomic neurotransmitter imbalance
Autonomic neurotransmitter imbalance contributes to orthostatic hypotension, autonomic dysreflexia, cardiac arrhythmias, bladder dysfunction, and gastrointestinal motility disorders. Disruption of noradrenaline and acetylcholine signalling alters vascular tone, heart rate, smooth muscle contraction, and glandular secretion, explaining why autonomic disorders often present with fluctuating vital signs and multisystem involvement.
Neurotransmitter systems also explain why neurological injury can worsen over time. After stroke, traumatic brain injury, or hypoxia, damaged neurons release excessive glutamate, triggering excitotoxicity that injures surrounding cells and expands the area of damage. This secondary injury contributes to ongoing neurological deterioration and highlights the importance of early neuroprotective and supportive care.
Concept Check
Why does excessive glutamate activity cause neuronal injury?
How do GABA and glutamate work together to stabilise neural networks?
Why does dopamine loss in the basal ganglia impair movement initiation?
How does acetylcholine function differently at the neuromuscular junction versus in the autonomic nervous system?
Why do many psychiatric medications take weeks to reach full effect despite acting on neurotransmitters immediately?